Improving Cancer Care and Drug Development with Methylation Data
Register here
![GH Webinar](/wp-content/uploads/gw-webinar.png)
![Sponsored by Guardant Health](/wp-content/uploads/guardant-sponsor.png)
Summary
In this webinar, Evi Lianidou, professor of clinical chemistry at the University of Athens, and Jacob Berchuck, medical oncologist at Dana-Farber Cancer Institute, will discuss how integrating methylation data in liquid biopsy applications can accelerate novel oncology therapeutics development.
Duration: 62 minutes
They will discuss applications including:
- Methylation based gene silencing in breast, prostate, and lung cancer.
- Detecting cell-free DNA based methylation signal for low shedding tumors.
- Identifying novel predictive or prognostic markers to differentiate responders and non-responders.
- Accelerating novel oncology drug development.
Speakers
![](https://guardanthealth.com/wp-content/uploads/evi_s_headshot.jpg)
Evi Lianidou, PhD
Evi Lianidou is a professor of analytical chemistry and clinical chemistry in the department of chemistry at the University of Athens.
![](https://guardanthealth.com/wp-content/uploads/jacob_berchuck_headshot.jpg)
Jacob Berchuck, MD
Jacob Berchuck is a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center.
![](https://guardanthealth.com/wp-content/uploads/han_yu_chang.jpg)
Han-Yu Chuang, PhD
Han-Yu Chuang is the vice president of technology at Guardant Health.